Effect of Alirocumab on Mortality After Acute Coronary Syndromes

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Previous proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor trials showed reduced cardiovascular events but not mortality.
• The ODYSSEY OUTCOMES trial investigated alirocumab's effect on death following an acute coronary syndrome (ACS).

Purpose of the Study:

• To evaluate the impact of alirocumab on all-cause mortality and its components in patients post-ACS.
• To assess the relationship between achieved low-density lipoprotein cholesterol (LDL-C) levels and mortality benefit.

Main Methods:

• A double-blind, randomized trial involving 18,924 patients with recent ACS and elevated LDL-C on statin therapy.
• Alirocumab dosage was titrated to achieve LDL-C between 25-50 mg/dL; outcomes were compared against placebo.
• Log-rank testing and joint semiparametric models were used to analyze death and cardiovascular events.

Main Results:

• Alirocumab reduced all-cause death (HR 0.85, P=0.03) over a median 2.8-year follow-up.
• A significant mortality benefit was observed in a prespecified analysis of patients with ≥3 years follow-up (HR 0.78, P=0.01).
• Greater mortality reduction was seen in patients with baseline LDL-C ≥100 mg/dL and with achieved LDL-C levels around 30 mg/dL.

Conclusions:

• Alirocumab, when added to intensive statin therapy, may reduce mortality post-ACS.
• Treatment duration of ≥3 years, baseline LDL-C ≥100 mg/dL, and achieving low LDL-C levels enhance the mortality benefit.